27 related articles for article (PubMed ID: 11448928)
1. MHY1485 enhances X-irradiation-induced apoptosis and senescence in tumor cells.
Sun L; Morikawa K; Sogo Y; Sugiura Y
J Radiat Res; 2021 Sep; 62(5):782-792. PubMed ID: 34265852
[TBL] [Abstract][Full Text] [Related]
2. Bioactive Olivacine Derivatives-Potential Application in Cancer Therapy.
Tylińska B; Wiatrak B
Biology (Basel); 2021 Jun; 10(6):. PubMed ID: 34205757
[TBL] [Abstract][Full Text] [Related]
3. The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.
Clémenson C; Jouannot E; Merino-Trigo A; Rubin-Carrez C; Deutsch E
Invest New Drugs; 2013 Apr; 31(2):273-84. PubMed ID: 22810221
[TBL] [Abstract][Full Text] [Related]
4. n-3 polyunsaturated fatty acids decrease mucosal/epidermal reactions and enhance antitumour effect of ionising radiation with inhibition of tumour angiogenesis.
Wen B; Deutsch E; Opolon P; Auperin A; Frascogna V; Connault E; Bourhis J
Br J Cancer; 2003 Sep; 89(6):1102-7. PubMed ID: 12966433
[TBL] [Abstract][Full Text] [Related]
5. [What do we know about the mechanisms of the time factor in oncological therapy?].
Petersen C; Baumann M
Strahlenther Onkol; 2000 Oct; 176(10):443-7. PubMed ID: 11068587
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo pharmacological characterizations of the antitumor properties of two new olivacine derivatives, S16020-2 and S30972-1.
Malonne H; Farinelle S; Decaestecker C; Gordower L; Fontaine J; Chaminade F; Saucier JM; Atassi G; Kiss R
Clin Cancer Res; 2000 Sep; 6(9):3774-82. PubMed ID: 10999772
[TBL] [Abstract][Full Text] [Related]
7. In vitro cytotoxicity of S16020-2, a new olivacine derivative.
Léonce S; Perez V; Casabianca-Pignede MR; Anstett M; Bisagni E; Pierré A; Atassi G
Invest New Drugs; 1996; 14(2):169-80. PubMed ID: 8913838
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
9. NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity.
Salloum RM; Jaskowiak NT; Mauceri HJ; Seetharam S; Beckett MA; Koons AM; Hari DM; Gupta VK; Reimer C; Kalluri R; Posner MC; Hellman S; Kufe DW; Weichselbaum RR
Cancer Res; 2000 Dec; 60(24):6958-63. PubMed ID: 11156396
[TBL] [Abstract][Full Text] [Related]
10. In vivo antitumor activity of S16020, a topoisomerase II inhibitor, and doxorubicin against human brain tumor xenografts.
Vassal G; Merlin JL; Terrier-Lacombe MJ; Grill J; Parker F; Sainte-Rose C; Aubert G; Morizet J; Sévenet N; Poullain MG; Lucas C; Kalifa C
Cancer Chemother Pharmacol; 2003 May; 51(5):385-94. PubMed ID: 12736760
[TBL] [Abstract][Full Text] [Related]
11. The olivacine S16020 enhances the antitumor effect of ionizing radiation without increasing radio-induced mucositis.
Maggiorella L; Frascogna V; Poullain MG; Berlion M; Lucas C; Razy SD; Eschwege F; Bourhis J
Clin Cancer Res; 2001 Jul; 7(7):2091-5. PubMed ID: 11448928
[TBL] [Abstract][Full Text] [Related]
12. Acronycine derivatives as promising antitumor agents.
Guilbaud N; Léonce S; Tillequin F; Koch M; Hickman JA; Pierré A
Anticancer Drugs; 2002 Jun; 13(5):445-9. PubMed ID: 12045455
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
